What are common bioequivalence study mistakes?
Learn about the most common bioequivalence study mistakes drug developers make and the differences between…
Certara2026 年 3 月 20 日
Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer
Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…
Certara2026 年 3 月 19 日
Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026
Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…
Certara2026 年 3 月 11 日
Navigate GxP Compliance in the Cloud with Confidence
Master SaaS GxP compliance with risk-based computer system validation (CSV) aligned to GAMP 5, FDA,…
Certara2026 年 3 月 6 日
Understanding and calculating steady state pharmacokinetics
Steady state pharmacokinetics can seem abstract and confusing. Read this blog to gain a better…
Ana Henry2026 年 3 月 5 日
Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer
This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…
Danielle Pillsbury2026 年 3 月 4 日
ADC first-in-human (FIH) dose selection: Designing FIH studies for success
Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…
Certara2026 年 3 月 3 日
